Myrio-light-text-uai-258×101Myrio-light-text-uai-258×101Myrio-light-text-uai-258×101Myrio-light-text-uai-258×101
  • Home
  • Science
  • Technology
  • Pipeline
  • Team
  • News & Media
  • Contact us
✕

News & Media

April 15, 2025
April 15, 2025

Myrio at AACR 2025

March 14, 2025
March 14, 2025

Myrio Showcases Innovative KRAS Immunotherapy Research at SITC Spring Edition, San Diego March 12-14th 2025

November 12, 2024
November 12, 2024

Merck Announces Psaio Tx as finalist prize winner in their Emerging Biotech Grant Program at Ausbiotech 2024

April 8, 2024
April 8, 2024

Myrio Therapeutics awarded CUREator grant for pandemic preparedness research

April 8, 2024
April 8, 2024

Myrio Therapeutics data published in Nature: unlocking new targets for antibody-based therapies

April 8, 2024
April 8, 2024

CoVIC consortium publishes Global study on variant-resistant SARS-CoV-2 epitopes in Science

April 8, 2024
April 8, 2024

CAR TCR Summit: Myrio Tx shares transformational approach to targeted human antibody-based therapies

Melbourne HQ
Myrio Therapeutics Pty Ltd
6-16 Joseph Street
Blackburn North, VIC 3130
Email: info@myriotx.com

Myrio welcomes discussions with interested partners on advancing and commercialising immuno-therapies for patients globally.

Partnership enquiries: partnerships@myriotx.com

© 2024 MyrioTx Website. All rights reserved. Privacy Policy. Powered by Optix Digital Pty Ltd

We acknowledge the Wurundjeri people as the Traditional Owners of the land on which we work.
We recognise their continuing connection to Country and community.

Make an appointment